Recently, our high-coverage epigenomics study of the human aorta and carotid arteries has identified atherosclerosis-specific DNA methylation profiles that are lesion gradeindependent and are, therefore, established relatively early Objective-To understand whether cerebrovascular events, a major complication of atherosclerosis, are associated with any specific DNA methylation changes in the carotid plaque. Approach and Results-We profiled the DNA methylomes of human symptomatic carotid plaques obtained from patients who had cerebrovascular events (n=19) and asymptomatic counterparts (n=19) with a high-density microarray (≈485 000 CpG sites, Illumina), and crossed DNA methylation data with RNAseq-based expression data from an independent symptomatic carotid plaque set (n=8). Few (30) CpGs showed a significant (P<0.05; absolute Delta-Beta, >0.20) differential methylation between the 2 groups. Within symptomatic carotid plaques, DNA methylation correlated significantly with postcerebrovascular event time (range, 3-45 days; r-value range, −0.926 to 0.857; P<0.05) for ≈45 000 CpGs, the vast majority of which became hypomethylated with increasing postcerebrovascular event time. Hypomethylation was not due to erasure of the gene-body and CG-poor region hypermethylation that accompany the progression of stable lesions, but rather targeted promoters and CpG islands. Noticeably, promoter hypomethylation and increased expression of genes involved in the inhibition of the inflammatory response, defense against oxidative stress, and active DNA demethylation were observed with increasing postcerebrovascular event time. Concomitantly, histological changes consistent with phagocyte-driven plaque healing were observed. Conclusions-Weak changes in the DNA methylome distinguish symptomatic from asymptomatic plaques, but a widespread demethylation resulting in permissive transcriptional marks at atheroprotective gene promoters is established in plaques after a cerebrovascular event, thus mirroring previous observations that ruptured plaques tend to revert to a stable structure. The identified loci are candidate targets to accelerate the pace of carotid plaque stabilization. (Arterioscler Thromb Vasc
D NA methylation is an important epigenetic mechanism of transcriptional regulation. 1, 2 The DNA methylome undergoes programmed changes during cellular differentiation, but it can also be modified by exogenous stimuli such as the diet and environmental factors, some of which coincide with known atherosclerosis risk factors. 2, 3 Therefore, it has been proposed that the latter may act by imposing aberrant, proatherogenic DNA methylation patterns. 4, 5 Indeed, differentially methylated sites mapping to genes participating in atherogenesis have been identified by candidate gene-based studies and in a recent epigenome-wide survey of normal and atherosclerotic human aortas, which showed a genome-wide increase in DNA methylation in atherosclerosis. [6] [7] [8] Accordingly, biochemical inhibition of DNA methyltransferase activity decreases vascular lesion size in mice. 9, 10 Furthermore, epigenome-wide association studies have linked peripheral blood cell DNA methylation profiles of specific loci to hyperlipidemia, hyperglycemia, and obesity, thus uncovering candidate circulating epigenetic markers of atherosclerosis and metabolic diseases predisposing to atherosclerosis. [11] [12] [13] during the natural history of the atheroma. 8 One pending issue is, therefore, whether any DNA methylation profile is associated with plaque rupture, the most common underlying cause of the clinical complications of advanced atherosclerosis. Furthermore, as ruptured plaques remodel to a relatively stable structure after stroke events, 14 we asked whether DNA methylation at specific loci changes with time after the postcerebrovascular event time (PCET). To answer these questions, we compared the DNA methylation profiles of symptomatic carotid plaques (SCPs) and asymptomatic counterparts (ACP) and we sought DNA methylation profiles that correlate with PCET in the symptomatic sample set.
For both the described analyses, we exploited a highcoverage DNA methylation microarray 15 that determines the methylation status of >450 000 CpG sites in the human genome.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. A schematic flowchart showing the source of the samples and the techniques used is shown in Figure 1 .
Results

Comparison of DNA Methylation Profiles of Symptomatic and Asymptomatic Carotid Atherosclerotic Plaques
We sought to identify specific differentially methylated loci between carotid plaques that were either ACP or SCP (n=19 in each group). The ACP and SCP sample sets showed a significant difference in age (ACP, 67.9+5.4 years; SCP, 74.0+8.7 years; unpaired t test P=0.014) but not in sex distribution (% male ACP, 68.4; SCP, 78.9; χ 2 test P=0.796). The DNA methylation analysis was conducted by using the Infinium HumanMethylation450 BeadChip (450k array), a high-density DNA methylation array that interrogates ≈485 000 human CpGs. 15 We compared the ACP and SCP sample sets by clustering analysis and by individual CpG methylation profiling. First, unsupervised clustering analysis could not distinguish the 2 samples, suggesting that plaque rupture-specific DNA methylation profiles are either weak or limited to a subset of the cells within the plaque ( Figure I in the online-only Data Supplement). Second, a detailed CpG-level analysis revealed modest differences between the ACP and SCP samples. Delta-Beta values were comparatively low, with only 30 autosomal CpGs passing the low stringency criterion of an absolute SCP-ACP Delta-Beta, >0.20 (range, −0.29 to 0.34). This CpG set will be referred to as SA (symptomatic vs asymptomatic atheroma)-CpG (Table 1) . SA-CpGs and the previously identified aortic lesion grade-independent DNA methylation profiles (dm-CpGs) 8 showed little overlap: no CpG was identical in the 2 sets and 1 hypermethylated dm-CpG (cg08894593) mapped 8.5kb from a SA-CpG (cg08136432) in the lysosomal exohydrolase N-acetylgalactosamine-6-sulfatase (GALNS) gene-body. Various loci mapped to genes involved in pivotal biological processes in atherosclerosis, such as inflammation, the immune response, and extracellular matrix homeostasis ( Table I in the online-only Data Supplement). For example, 5 CpGs all hypermethylated in SCPs clustered within a ≈30 kbp region of the HLA-DRB locus, which is involved in the immune response in atherosclerosis. 16 Other noticeable cases are 2 genes involved in oligosaccharide sulfation (CHST8 and GALNS), an enzymatic reaction involved in lymphocyte homing by the endothelium, 17 and the metallopeptidase inhibitor TIMP2, a regulator of the homeostasis of the extracellular matrix. 18 To assess the reproducibility of the 450k array data for the ACP-to-SCP comparison, pyrosequencing was performed for 3 of the 31 SA-CpGs in 2 relevant genes (cg24760581 and cg10385522 in the HLA-DRB1 promoter; cg15290312 in the TIMP2 gene-body). Pyrosequencing results were in excellent agreement with 450k array data (r=≥0.91; P<0.0001 in all cases; data not shown). Despite the pathological relevance and successful validation, no CpG reached significance after Bonferroni correction for multiple testing (P<10 −7 ; unpaired t test). Taken together, both the clustering analysis and detailed CpG-specific profiling revealed a pathobiologically plausible but weak DNA methylation profile that could differentiate the SCP from the ACP.
DNA Methylation Variation After Cerebrovascular Events
Next, we assessed whether DNA methylation changes with increasing PCET. To this end, we sought CpG loci with a significant correlation (Pearson correlation test followed by adjustment for the parameters listed in Table II in the onlineonly Data Supplement) between methylation status and PCET in the SCP sample set (n=19). PCET was in the 3-to 45-day range. A significant correlation that resisted adjustment (uncorrected P<0.05; corresponding to an absolute Pearson r>0.4556 for n=19) was detected for a noticeably large number of CpGs (45 214 or ≈10% of all array probes). The r-value range was −0.926 to 0.857 (P=10 −8 and 2.8×10 −6 , respectively). This CpG set will be referred to as PCET-CpGs. The vast majority of PCET-CpGs became hypomethylated with increasing PCET (36 999 or 81.8%). To better understand the trend of CpG methylation with increasing PCET, we compared the average methylation β value for the identified 45 214 PCET-CpGs in the following 3 groups, such as (1) the upper quartile (late) PCET set (referred to as late-PCET; range, 36-45 days; n=5); (2) the lowest quartile (early) PCET set (early-PCET; range, 3-9 days; n=3); and (3) the ACP set (n=19). The latter was included as a reference to appreciate the extent of the PCET-related DNA methylation drift. When the differences between pairs of these 3 sample sets were plotted by increasing methylation-to-PCET Pearson r value, a clear stratification was observed ( Figure 2 ). In the PCET-CpG set that became hypomethylated with increasing PCET (left of dashed vertical line in Figure 2 ), the late-PCET was hypomethylated relative to the early-PCET set (late-PCET−early-PCET Delta-Beta, <0; average, −0.020) and noticeably was also hypomethylated relative to ACP, although to a lesser extent (average late-PCET−ACP Delta-Beta, −0.012). As implied by those data, early-PCET was hypermethylated relative to ACP (average Delta-Beta, 0.008).
Despite showing relatively small Delta-Beta differences, the β values of the late-PCET, early-PCET, and ACP sets revealed significant differences in any comparison among the 3 (P<10 −20 in all cases; paired t test). In summary, we identified CpG loci that underwent hypermethylation in the transition from ACP to early-PCET-that is, from an asymptomatic plaque to 1 associated with recent symptoms-and reversed their methylation status with increasing PCET actually to levels beyond the ones of ACP. The opposite trend was observed for the PCET-CpG set that was hypermethylated with increasing PCET (right of dashed vertical line in Figure 2 ). Remarkably, only 1 of the 45 214 PCET-CpGs (cg18160841, intergenic) was common between the previously identified aortic lesion grade-independent DNA methylation profiles (dm-CpGs) 8 and PCET-associated methylation profiles, and showed opposite changes in methylation in the 2 sets-that is, hypermethylated in atherosclerotic aortas and hypomethylated with increasing PCET. This limited overlap suggests that PCET-associated DNA methylation profiles do not result from the reversal of dm-CpG methylation. To understand the genomic context and functional impact of PCET-associated CpG methylation, we analyzed in detail a subset of 3894 of the initial 45 214 PCET-CpGs, showing the highest absolute Pearson r values. The rationale for this choice was that the corresponding number of genes (2920) was just below the maximum accepted by the DAVID gene functional annotation database. This PCET-CpG set is listed in Table III in the online-only Data Supplement. The DNA methylation trend of this PCET-CpG subset was even more dramatically skewed than the original complete PCET-CpG set, as 3539 or 90.9% of those PCET-CpGs were hypomethylated with increasing PCET. Clustering analysis clearly shows that PCET-CpGs tend to group according to the PCET and that demethylation with increasing PCET is the main trend of this CpG subset (Figure 3 ). The genomic location of the PCET-CpG subset was significantly skewed toward promoters, 5′ untranslated region (UTR) and first exons (P=9.9×10 −6 relative to the whole 450k array probe distribution, χ 2 test) and CpG islands (CGIs; P=2.4×10 −13 ), with a clear progressive underrepresentation moving away from CGIs toward open sea ( Figure 4A and 4B) . The vast majority (1913 or 81.2%) of the 2357 genic CGIs in this PCET-CpG subset, mapped to the 5′ regulatory gene portion.
As for gene function, a large number of the 2919 genes harboring this PCET-CpG subset (2375 or 81.4%) were targets of the POU class 2 homeobox 1 (POU2F1, alias OCT-1) transcriptional repressor (false discovery rate=7.3×10 −15 ). POU2F1 downregulates atheroprotective and anti-inflammatory genes in response to oxidized low-density lipoprotein in the endothelium. 19 Examples of POU2F1-regulated genes are the cytochrome P450 monooxygenases (CYP), which generate anti-inflammatory epoxy-fatty acid derivatives and the atheroprotective liver X receptor ligand oxysterol leading to ATP-binding cassette (ABC) cholesterol transporter activation. [20] [21] [22] Accordingly, the promoters of various CYP and ABC family genes were hypomethylated with increasing PCET, suggesting a release of transcriptional repression of these atheroprotective genes ( Table 2 ). Another example is the myocyte enhancer factor 2 C (MEF2C), a suppressor of the inflammatory response. 23 These findings suggested that other genes involved in the control of cellular oxidation reactions underwent similar epigenetic changes. Indeed, the analysis of the initial 45 214 PCET-CpG set revealed that known players in cellular defense against oxidation-that is, members of the glutathione peroxidase (GPX), superoxide dismutase (SOD), thioredoxin reductase (TXNRD), and thioredoxin (TXN) families [24] [25] [26] with increasing PCET. Noticeably, within the 4 endothelial NADPH oxidases (NOX), the only atheroprotective isoform is NOX4, 27 which was the only NOX gene undergoing promoter hypomethylation in our sample. Importantly, the promoter of ten-eleven translocation-2 (TET2) was hypomethylated with increasing PCET. TET2 is a dioxygenase responsible for the conversion of methylated cytosines to oxidized derivatives that are excised and replaced with unmethylated cytosines, thus resulting in DNA demethylation. 28 The relevance of TET2 in atherosclerosis is suggested by the observation that its expression decreases with smooth muscle dedifferentiation and in advanced compared with low histological grade human plaques, or in macrophages challenged with oxidized low-density lipoprotein. 29, 30 Another noticeable finding is the hypomethylation of a gene-body CpG of the connective tissue growth factor (CTGF) gene-body, recently identified as a stabilizer of the atherosclerotic plaque. 31 A concerted hypomethylation of various promoter CpGs was observed for many of the aforementioned genes, which is suggestive of an instructive, nonrandom mechanism.
To assess the impact of PCET-CpG hypomethylation on transcription, we analyzed RNAseq-derived expression data from an independent set of human carotid plaques from symptomatic patients (n=8). Noticeably, 5′ region hypomethylation was generally accompanied by an increase in expression with PCET for the relevant atheroprotective genes mentioned above ( Table 2 ). Another remarkable gene that underwent concomitant promoter hypomethylation and increased expression with PCET was TP53INP2, which is essential for autophagy in mammals and may mediate plaque stabilization by phagocyte-mediated rupture repair. 32 PCET-associated 5′ region CpG hypomethylation and corresponding expression trends for the relevant CYP2U1, MEF2C, and TET2 genes are shown in Figure 4C and 4D as examples. For the latter genes and in other relevant cases (SOD1 and GPX3), expression increased by 2-to 4-fold with PCET. However, gene-body hypomethylation was associated with weak transcriptional changes or repression. Remarkably, the latter group included the TNF-αinduced and proinflammatory TNFAIP3 (also known as A20), TXNL1 and TXNIP genes [33] [34] [35] (Table 2) . Unexpectedly, the candidate plaque stabilizing CTGF showed a similar trend. 31 The functional profile of PCET-CpG-harboring genes prompted us to seek histological evidence of plaque stabilization with PCET. We observed a significant increase of plaque CD68 expression, a phagocyte marker, with PCET (r=0.54; P=0.016; n=19), suggestive of phagocyte-driven plaque healing ( Figure II in the online-only Data Supplement). 36 Alpha-actin, a marker of differentiated, often plaque stabilizing smooth muscle, tended to increase with PCET (r=0.27; P=0. 26) and was twice more abundant in late-PCET compared with early-PCET plaques (18.2%+7.7% and 8.6%+6.2% of plaque section area, respectively) although not significantly.
The 3894 PCET-CpG subset minimally overlapped with the previously identified aortic atherosclerosis-associated, lesion grade-independent dm-CpGs. 8 No CpG was common to the 2 sets, and only 148 genes (or 5.0% of the 2919 PCET-CpG subset-harboring genes) harbored CpGs of both sets. In the majority of those 148 common genes (98 or 66.2%), promoter PCET-CpG hypomethylation contrasted with the hypermethylation of gene-body or promoter in the dm-CpG set. Furthermore, the genomic distribution of PCET-CpGs is statistically different from the one of dm-CpGs, which are biased toward open sea and gene-bodies (P=2.0×10 −200 and P=1.8×10 −32 relative to CGIs and gene compartments, respectively). 8 We next asked whether any of the aforementioned differentially methylated CpGs between SCPs and ACPs (SA-CpGs) CGI; B) . Open and solid bars indicate the observed probe distribution and the probe distribution in the 450k array (expected distribution), respectively. C, Example of promoter methylation trend for the CYP2U1, MEF2C, and TET2 genes with increasing PCET. The corresponding CpG ID and gene are indicated within the graph. D, Expression trend with increasing PCET for the same genes shown in (C). The untransformed normalized expression levels rather than their log 2 counterparts are used to convey a more intuitive information on the expression changes with PCET.
underwent similar epigenetic changes with increasing PCET. Of the 17 SA-CpG-harboring genes, PCET-associated promoter hypomethylation was observed for MRPL1 and GALNS. Finally, we asked whether the observed PCET-related global CGI demethylation may explain previously published data showing the same trend in selected somatic CGIs in atherosclerosis. 37 The latter study was based on a relatively low coverage CGI array, and identified 23 genic CGIs that were demethylated in ruptured coronary lesions of patients with myocardial infarction, compared with normal aortic root tissue. Of those, 18 (or 78.3%) overlapped with the complete 45 214 PCET-CpG set, and 16 mapped to the same genic compartment (promoters: C11orf45, CAMK1D, FAU, GNB1L, HERC5, MUTED, ZNF506; 5′UTR/first exon: CAPZB, CHCHD8, EGFL7, GORASP1, LIF; gene-bodies: FOXP1, GSC, MYOM2, ZNF821).
Discussion
We previously showed that a prominent epigenetic signature common to aortic and carotid atherosclerotic plaques is DNA hypermethylation independent of histological grade, suggesting that atherosclerosis-specific DNA methylation profiles are established at relatively early stages of plaque evolution. 8 This work expands the description of the dynamics of DNA methylation in atherosclerosis, as our data indicate that after that early hypermethylation, the carotid plaque DNA methylome undergoes relatively minor changes with the appearance of cardiovascular symptoms, but subsequently drifts toward a widespread hypomethylation with increasing PCET. The early hypermethylation and PCET-associated hypomethylation events involve distinct genomic regions and genes: the former targets preferentially gene-bodies and CG-poor regions located >4 kb away from CGIs, whereas PCET-associated hypomethylation maps mainly to CGIs and promoters. In addition, PCET-CpGs and the previously described histological grade-independent atherosclerosis-specific dm-CpGs 8 show little overlap: they involve distinct CpG loci with opposite DNA methylation trends and in distinct gene compartments. The same conclusion is reached after analyzing target gene function: dm-CpGs map mainly to genes involved in smooth muscle dedifferentiation, whereas PCET-associated hypomethylation coordinately targets the promoter of genes involved in various atheroprotective pathways: negative regulation of inflammation, oxidative stress defense, autophagy, response to estrogen. Taken together, these differences indicate that the PCET-CpG hypomethylation is not produced by the erasure of dm-CpG hypermethylation, but by a distinct de novo mechanism. Promoter hypomethylation is a permissive epigenetic mark, therefore, the observed changes after a cerebrovascular event suggest a process of plaque remodeling to a milder atherosclerotic and more stable phenotype. 14 We also provide histological evidence consistent with an increased phagocyte-mediated plaque repair and a tendency for differentiated smooth muscle cells to become more abundant with PCET. In accordance with DNA methylation data, the expression of several of the aforementioned genes increased with PCET. The fact that the expected relationships between promoter methylation and expression are observed in independent SCP set, supports a wide pathobiological significance for our data. In particular, we identified a progressive TET2 promoter hypomethylation and increased expression with PCET as a candidate pivotal epigenetic change contributing to both DNA demethylation and plaque stabilization with increasing PCET, in line with recent literature. 29 Nonetheless, the observed promoter methylation changes are in some cases relatively small, suggesting that other transcriptional mechanisms act in coordination with DNA demethylation to produce the observed gene expression trends. Furthermore, our data may account for the conflict between studies that point to opposite trends in DNA demethylation in atherosclerosis. [37] [38] [39] For example, the net CGI demethylation observed in coronary lesions of patients with myocardial infarction in our previous work, is consistent with the postrupture trend shown here. 37 The paucity of DNA methylation differences between symptomatic and asymptomatic carotid atheromas suggest that plaque rupture is associated with DNA methylation profiles that are either quantitatively weak or are specific for only in a minority of the cells populating the plaque. Indeed, current views attribute plaque rupture to proteases expressed by a subpopulation of proinflammatory macrophages residing in the plaque shoulder. 40, 41 Sample size alone cannot explain our result, as significant differences in DNA methylation were previously observed across a smaller sample of aortic atheromas. 8 In line with our findings, no significant difference in blood DNA methylation was observed among patients with ischemic stroke subtypes, despite differences in pathogenesis. 42 Other epigenetic marks besides DNA methylation may participate in plaque rupture, as the histone deacetylase HDAC3 has been recently shown to silence genes that favor plaque stability. 43 Further studies in specific cell populations within lesions are warranted to assess the pathobiological relevance of the candidate plaque rupture-associated DNA methylation profiles presented here.
In conclusion, our work identifies CpG loci that are candidate targets to improve carotid plaque stability. Specifically, our data and recent data in a mouse model 9, 10 suggest that the inhibition of the DNA methylation machinery may produce the compounded benefit of both slowing the DNA hypermethylation associated with plaque progression and favor the stabilization of advanced atheromas, thus lowering the burden of the clinical complications of atherosclerosis. 
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